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ABSTRACT
25-Hydroxyvitamin D, IGF-1, and Waist Circumference A Cross-Sectional Study
by
Damon McCune
Dr. Laura Kruskall, Examination Committee Chair
Associate Professor, Director of Nutrition Sciences
University of Nevada, Las Vegas

Purpose: Waist circumference has been shown to have a link to various forms of chronic
disease and low levels of Vitamin D (25(OH)D) and IGF-1. The purpose of this study is
to assess if there is a relationship with Vitamin D (25(OH)D) and IGF-1 levels and waist
circumference.

Methods: As part of a cross-sectional correlation study, participants were males and
females (n=26), ages 25-65, who were students at UNLV and/or individuals who attend

local health and wellness facilities as well as attendees of classes held by the UNLV
Nutrition Center. Participants reported to UNLV to review and sign informed consent

and submit a finger stick blood draw under sterile conditions as well as resting blood
pressure and waist circumference. The finger stick blood draw sample was used to

obtain serum 25(OH)D and IGF-1 levels using ELISA kits. Participants completed food
frequency questionnaires asking about eating habits prior to study and surveys were
administered to determine level and type of physical activity. Participants then reported

to a local Quest Diagnostics at their convenience to obtain a fasting comprehensive
metabolic panel. Data were collected and evaluated using Microsoft Excel and SPSS
software.

iii

Results: Subjects were separated into two groups according to waist circumference
(Female >35”, Male >40”) Data reflected no significant difference between large waist
and normal waist circumference groups in regards to both IGF-1 and 25(OH)D. Data did
reflect, however, that a significant relationship between IGF-1 and waist circumference
did exist (P=.006). Although, a significant relationship between 25(OH)D and waist
circumference did not exist.
Conclusion: Waist circumference has an inverse relationship to IGF-1. Abdominal
obesity may cause a reduction in the amount of free IGF-1 produced by the body which
could increase risk for chronic disease. Obtaining waist circumference as well as
activity level is relatively convenient in medical treatment settings and could
provide clinicians with more valuable information regarding patient’s level of risk
for disease.

iv
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CHAPTER 1
INTRODUCTION
Risk of Abdominal Obesity
Waist circumference has been shown to be reflected to many aspects of
adverse health conditions including cardiovascular disease (CVD), hypertension,
hyperlipidemia, and diabetes mellitus. Since CVD is the leading cause of morbidity
and mortality in many countries worldwide, the high correlation to waist
circumference and risk of CVD needs to be further investigated. 1
Conditions Associated with Abdominal Obesity-Metabolic Syndrome
Waist circumference has also been linked to indicators of Metabolic
Syndrome. Metabolic syndrome is the co-occurrence of the health conditions
previously mentioned related to waist circumference. While this body of work will
not be focusing on all indicators of Metabolic Syndrome, understanding the
conditions associated with Metabolic Syndrome and how those relate to waist
circumference is crucial. To assess Metabolic Syndrome, it is important to
understand that it is not a condition defined by one disease condition but rather a
cluster of several co-occurring cardiovascular risk factors that significantly increase
an individual’s risk for a cardiovascular event. These factors include; insulin
resistance, hypertension, atherogenic dyslipidemia, and obesity (mainly abdominal
obesity).1 Although these factors all have individual parameters for diagnosis and
individual health threats, when combined they pose increased risk for a
cardiovascular event to occur even if they only carry a borderline diagnosis. All may
be controlled through dietary and lifestyle changes.
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Insulin resistance is a condition in which the body produces insulin but does
not utilize it properly. The biochemistry of this action can be described partially by
the binding of insulin mainly to insulin receptors on cells and also through insulin
like growth factor-1 (IGF-1) receptors. IGF-1, a polypeptide hormone, plays a role in
proliferation and differentiation of cells and has apoptosis properties. These traits
may be the reason it has a relationship to chronic diseases. Insulin sensitivity can be
adversely altered due to obesity, in particular abdominal obesity.² Cellular actions of
insulin depend on a wide variety of effects on post receptor signaling pathways
within target cells. The beta subunit of the insulin receptor is a tyrosine kinase,
which is activated when insulin binds to the alpha subunit. The kinase
autophophorylates and mediates multiple activities of insulin. Insulin receptor
concentration or affinity may be altered due to obesity, physical inactivity, ambient
insulin levels, various physiological and disease states, and drugs. The secretion of
insulin and insulin sensitivity are reciprocally related which means that insulin
resistance results in an increase in insulin secretion to maintain normal glucose and
lipid homeostasis. There is also an inverse association between serum 25(OH)D and
insulin resistance. Some researchers hypothesize that the insulin resistance is
caused by low levels of circulating 25(OH)D, while other researchers believe that
obesity, in particular central obesity, is the cause of both low levels of circulating
25(OH)D and insulin resistance.²¯³
The final component of metabolic syndrome is obesity. Some believe this to
be the cause and others find it as a byproduct to the other conditions associated.
Regardless of the view of this condition, it plays a major role in the risk and systemic
2

pathophysiology of cardiovascular disease. It should be noted that having too much
body fat is considered different from being overweight, or simply weighing too
much. The most common measurement of obesity is the Body Mass Index (BMI), and
is a measurement of height (in meters)/weight (in kilograms2). A normal range is
between 18-25 m/kg2, overweight is considered between 25-29.9 m/kg2, obese is
considered over 30 m/kg2, and underweight is below 18 m/kg2. Recent literature
has introduced a modified approach to also include abdominal obesity to the
measurement by including a waist circumference measurement. This method is
referred to as the Body Shape Index (ABSI), and was introduced by Nir Krakauer, et
al. The ABSI formula is WC/(BMI⅔Height1/2).1
Population at Risk
An accumulation of body fat, usually twenty percent or more over an
individual’s ideal body weight is also considered to make an individual obese and
increases risk for chronic disease. The accumulation of excess body fat in the
abdominal area in particular also increases risk for cardiovascular events and
chronic disease. The cause of this condition is simply consuming more energy than
is expended by the body. While the cause of this condition is simple and easy to
counteract, gaining compliance from patients seems to be one of the most difficult
tasks facing medical professionals. 4
Clinical Indicators of Metabolic Syndrome
The National Cholesterol Education Program Adult Treatment Panel III (NCEPATP III) criteria was used to define large waistline and high fasting glucose. The
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NCEP-ATP III defines criteria of metabolic syndrome as any three of the following
traits in the same individual: 3


Large Waistline – Men: 40 inches (102cm) or more, and women: 35 inches
(88cm) or more.



High Triglycerides – 150 mg/dL or more



Low HDL Cholesterol – Men: 40 mg/dL or less, and women: 50 mg/dL or less



High Blood Pressure – 130/85 mmHg or more



High Fasting Glucose – 110 mg/dL or more

It has been shown that individuals borderline on these indicators also show an
increased risk for a cardiovascular event as well as those with extremely high
values. Also, according to the American Heart Association estimated $475.3 billion
cost for cardiovascular disease and stroke in the United States for 2009.5
Impact on Organs
Organs usually affected by metabolic syndrome include, but are not limited
to; heart, brain, pancreas, kidneys, lungs, liver, and arteries. The main organ
impacted by the condition would be the heart. Due to the increase in resistance of
blood flow in arteries, cardiac output is decreased thus forcing the heart to work
harder. This is compounded by the fluid retention that is common in those who are
obese or suffer from kidney complications which further increases strain to the
heart. To further add to this strain, liver complications can further increase
dyslipidemia in patients which also compounds these previously mentioned
complications to the heart. Finally, possibly at the forefront of the complications,
pancreatic dysfunction or insulin resistance does not allow for the utilization of
4

glucose and lipids properly. Lack of glucose to supply the brain with usable fuel can
lead to dysfunction systemically in the body including respiratory dysfunction and
all of these systemic complications, when co-occurring, compound each other and
further impose strain on the heart until it can no longer handle the load.
Individuals that meet criteria of metabolic syndrome are usually found to be
over-nourished and have a large waist circumference. These individuals are
generally not deficient in nutrients, although acute deficiency may occur depending
on lifestyle or secondary conditions. Among these deficiencies, vitamin D deficiency
seems to be one of the most prevalent conditions. These acute deficiencies are easily
manageable when compared to combatting the over-intake of macronutrients and
energy.4
The purpose of this study is to explore the relationship between 25hydroxyvitamin D (25(OH0D), IGF-1, and waist circumference.
Question 1: Is there a relationship that exists between 25(OH)D and waist
circumference?
Ho: Serum 25(OH)D levels have no association with waist circumference
H1: Serum 25(OH)D levels will be inversely associated with waist
circumference.
Question 2: Is there a relationship that exists between IGF-1 and waist circumference?
Ho: Serum free IGF-1 levels have no association with waist circumference.
H1: Serum free IGF-1 levels will be inversely associated with waist
circumference.
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Question 3: Do individuals with large waist circumference have lower levels of serum
IGF-1 than those with normal waist circumferences?
Ho: Individuals with large waist circumference will not have a lower level of
serum IGF-1 than those with normal waist circumference.
H1: Individuals with large waist circumference will have a lower level of
serum IGF-1 than those with normal waist circumference.
Question 4: Do individuals with large waist circumference have lower levels of serum
25(OH)D than those with normal waist circumference?
Ho: Individuals with large waist circumference will not have a lower level of
serum 25(OH)D than those with normal waist circumference.
H1: Individuals with large waist circumference will have a lower level of
serum 25(OH)D than those with normal waist circumference.
Recently, several studies have supported dietary and lifestyle approaches for
reducing risk factors related to cardiovascular disease (CVD) that provide
information as to why maintaining a healthy waist circumference is vital.

6

CHAPTER 2
REVIEW OF LITERATURE
Body Shape Index Validity
Recently, researchers have sought to produce a formula to include some form
of body composition to the Body Mass Index (BMI) even in complex settings when
conventional tools of measurement may not be accessible. This measurement could
provide clinicians with a more accurate depiction of risk in patients since the BMI
does not always reflect accurately on individuals whose weight is primarily skeletal
muscle with little body fat. Nir Krakauer, et al, introduced the Body Shape Index
(ABSI) to provide a useful and practical tool for those situations where patients are
non-ambulatory conventional composition tools are not available. 1
The World Health Organization (WHO) rank weight and obesity fifth among
causes of death worldwide. Validity of BMI-based obesity guidelines has come into
question since BMI does not distinguish between muscle and fat mass and
accumulation. Abdominal fat accumulation has been shown to increase risk of
disease more so than accumulation of fat in other areas of the body. This reflection
of increased risk has projected waist circumference (WC) as the leading compliment
to BMI.1
Research was focused on individuals using outcome data from the National
Health and Nutrition Examination Survey (NHANES) 1999-2004. Fourteen
thousand, one hundred and five individuals were sampled of all ages, races, and
gender. Z scores were calculated to control for age and gender. A fraction of
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population mortality hazard from high values was calculated and uncertainty in this
expression was approximated only to uncertainty in the numerator. 1
Krakauer, et al, followed up this initial research with a follow up to account
for limitations identified in the NHANES sample. Waist to hip ratio (WHR) and waist
to height ratio (WHtR) was not directly evaluated in initial sample. Also,
anthropometrics measurements were only taken on one occasion so there was no
way to assess ABSI over time. Follow up with participants was also relatively short
at five years which further raises cause for concern of accuracy of ABSI over time.
This body of work expanded samples to include information obtained from the
Health and Lifestyle Survey (HALS). Researchers introduced HALS data to analysis
methods, compared calculations to widely used anthropometric measures including
WHR, and evaluated mortality as a function of change spaced 7 years apart. This
research concluded that ABSI outperformed other measures of abdominal obesity as
an indicator of mortality. Also, ABSI was a consistent predictor of mortality over at
least 20 years of follow up. 2
Other researchers took notice to this new and seemingly effective formula for
obtaining risk of disease and applied it to populations in China to see if the
calculation could predict new onset diabetes mellitus (DM) in the general
population. Sen He, et al, applied the ABSI’s predictive power to the follow up data
collected over 15 years from a general Chinese population. 711 participants from an
urban community submitted data in 1992 and then again in 2007. Twenty four
participants were diagnosed with DM in 1992 so their data was excluded. Complete
data were obtained for 687 participants. Results supported the conclusion that ABSI
8

was an effective predictor of new onset diabetes mellitus. More research is needed
involving other populations to confirm if ABSI is an effective predictor of new onset
diabetes mellitus. 3
Causes of insulin resistance include genetic or primary target cell defects,
autoantibodies to insulin, and accelerated degradation of insulin. Mitochondrial
dysfunction may play an important role in development of insulin resistance and
complications. Obesity is the most common cause of insulin resistance due to the
association with decreased number of receptors and post receptor failure to activate
tyrosine kinase.⁴¯⁶ Physical inactivity also lowers the body’s sensitivity to insulin by
similar mechanisms to obesity. This condition seems to be the cornerstone for the
cause of other conditions involved with metabolic syndrome. Although, evidence
suggests that there is an inverse relationship between IGF-1 and Metabolic
Syndrome serum IGF-1 levels may be controlled to an extent with appropriate
nutrition and activity.²
The next condition contributing to metabolic syndrome is hypertension.
Blood pressure is the measurement of the force against the walls of arteries as the
heart pumps blood through the body. Hypertension is defined as a consistent
measurement of systolic over 130 or diastolic over 85 (NCEP-ATP III).⁴ Two types of
hypertension have been identified and are referred to as primary or essential
hypertension and secondary hypertension.
For most adults, primary hypertension has no identifiable cause of high
blood pressure. This type tends to develop gradually over many years and is the
result of several lifestyle factors including; diet (excess sodium intake, decreased
9

potassium intake), physical inactivity, smoking, stress, and obesity. Again,
abdominal obesity being most correlated. There are no symptoms of hypertension
so it may go years without any diagnosis.⁷
Secondary hypertension is high blood pressure caused by an underlying
condition. This condition tends to appear suddenly and cause a higher blood
pressure than primary hypertension. Various conditions and medications can lead
to secondary hypertension including; renal insufficiency or disease, adrenal gland
tumors, certain congenital blood vessel defects, or medications such as birth control
pills, cold remedies and decongestants, over the counter pain relievers, and
prescription medications. Neither primary nor secondary hypertension has visible
symptoms which is why hypertension is known as the “Silent Killer”.8
Another contributing factor in metabolic syndrome is atherogenic
dyslipidemia which is defined as a triad of increased blood concentrations of small,
dense low-density lipoprotein (LDL) particles, decreased high-density lipoprotein
(HDL) particles, and increased triglycerides. HDL levels in men are considered low if
under 40 mg/dL and under 50 mg/dL for women. Triglycerides are considered high
in either gender if over 150 mg/dL. When combined with hypertension, the elevated
LDL levels in the blood will react with cytokines released due to inflammation
within blood vessels. Damage is usually found at a branch of the vessel caused by
hypertension. LDL-cholesterol collects at the site of inflammation to form foam cells
which, after time will cause hardening and thickening of the arterial walls
compounding the problems associated with hypertension and increased cardiac
output. Causes contributing to dyslipidemia may be primary (genetic) or secondary
10

and include; sedentary lifestyle, excess intake of saturated fatty acids, cholesterol,
and trans-fatty acids, excess simple carbohydrate intake, alcohol abuse, chronic
kidney disease, hypothyroidism, and medications such as corticosteroids and
glucocorticosteroids.9 Much like hypertension, atherogenic dyslipidemia has little to
no visible symptoms until sever elevations are present. The relationship between
abdominal obesity and atherogenic dyslipidemia has been well established.
Therefore, this research will focus on relationships of abdominal obesity with less
information in current literature.
Those at risk for these conditions are individuals with poor eating habits and
sedentary lifestyles. Usually individuals who are consuming an excess of a certain
macronutrient such as saturated fat are also consuming an excess of energy as well.
This is usually accompanied by a sedentary lifestyle and the two behavioral habits
compound each other’s complications. Also, highly stressful lifestyles contribute to
increasing risk of conditions. Furthermore, risks for conditions of metabolic
syndrome as well as abdominal obesity increase with age. According to the Center
for Disease Control, thirty four percent of individuals over the age of twenty meet
the criteria for metabolic syndrome, men and women age forty to fifty nine are more
than three times likely to meet criteria than those age twenty to thirty nine, men
over age sixty are more than four times more likely to meet criteria than those age
twenty to thirty nine, and women over age sixty are more than six times likely to
meet criteria than those age twenty to thirty nine. 10
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25(OH)D and IGF-1
Further research supports the notion that vitamin D and IGF-1 are reduced
with obesity. Since IGF-1 shares is able to bind with insulin receptors on cells,
obesity leads to less insulin receptors to be present on cells for binding. A crosssectional cohort study conducted on primarily Caucasian individuals, age 45 years
exhibited that lower serum concentrations of vitamin D and IGF-1 have been
associated with adverse lipid profiles, hypertension, cardiovascular disease and
disturbed glucose metabolism. 6,810 participants were contacted to answer
questionnaires and submit blood sample to assess non fasting glucose and lipid
profiles as well as serum 25(OH)D and IGF-1 levels. 78% of participants completed
questionnaires and 81% submitted blood samples. Men resulted as having
disturbed glucose metabolism, high blood pressure, and high triglycerides, although,
low HDL-C and abdominal obesity was less prevalent in men. Abdominal obesity
was most the most common indicator of Metabolic Syndrome present in 94.5% of
men and 95.8% of women. All of these conditions will raise risk of metabolic
syndrome.11-14
IGF-1 levels are strongly associated with changes with production and
secretion of human growth hormone (HGH). Low secretion of HGH results in low
levels of IGF-1 and acromegaly results in increased IGF-1. Age and sex also impact
serum IGF-1 concentrations and at age 65 years, daily spontaneous secretion of HGH
is reduced by 50-70% thus causing a decline in IGF-1 progressively. Normally, the
male gender will exhibit a higher level of IGF-1 when compared to females of the
same age.¹⁵
12

Subtle changes in IGF-1 have also been linked to changes in blood pressure
(BP) and insulin sensitivity. IGF-1 levels in the upper normal range have produced
results of reduced BP, vascular tone, and increased insulin sensitivity.
Epidemiological studies have suggested IGF-1 levels in the lower normal range have
been associated with increased risk of heart disease and stroke. A study of 174
healthy individuals investigated IGF -1, IGFBP3, and intima-media thickness (IMT)
of carotid artery and found that IGF-1 levels were the best predictors of total
cholesterol and HDL-C.¹⁵
Studies investigating relationships between IGF-1 and atherosclerosis have
resulted in conflicting conclusions; some authors found a positive association
between IGF-1 and IMT in both men and women, while others found an inverse
association between IGF-1 and carotid IMT in healthy women.¹⁶
Even though normal IGF-1 ranges have been established based on age and
gender, they are quite contradictory. The normal reference range used in this study
was established and used by the Mayo Clinic, however, other organizations as well
as research studies have established various ranges as normal. The Mayo Clinic’s
range was used because it reflected the lowest reference range based on age and
gender. A study conducted on 1798 men and women age 25-85 years determined
IGF-1 concentrations using chemiluminescent immunometric assay. Quantile
regressions were then performed to calculate the 2.5 and 97.5 percentile. These
reference ranges were substantially higher than those established by the Mayo
Clinic.¹⁷
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Impact of Treatment on Vitamin D and IGF-1 Status
Historically, clinicians’ first instinct to combating large waistlines and high
levels of lipids and cholesterol in patients was to eliminate nearly all dietary fat in
the diet. An example of one of these diets that is still in use by many physicians
today is the Ornish Diet, developed by Dr. Dean Ornish. Dr. Ornish is a cardiologist
with many accolades who also happens to be a vegetarian. His diet plan
compliments his personal plant-based approach to reducing risk for coronary artery
disease (CAD). However, according to the research energy and protein restriction
may actually cause a reduction in serum IGF-1 and IGFBP3.¹²
Controversy exists in the effectiveness of following a plant-based diet to
lower serum lipids. Comparing the Ornish diet to other diets high in animal fat and
cholesterol resulted in unexpected outcomes. Subjects on a diet that did not limit
cholesterol intake showed a greater decrease in systolic and diastolic blood
pressures, a greater increase in insulin sensitivity, a greater decrease in
triglycerides, and an increase in HDL-C as well as a greater reduction in body mass
and body fat when compared to subjects following the plant-based diet. The only
category of secondary outcomes that the plant-based diet subjects showed a greater
reduction was LDL-C.¹¹ This information was supplied by a study comparing dietary
intake of whole eggs versus egg substitute among participants. In a randomized,
single-blind, parallel design study, 37 participants were recruited to either consume
3 whole eggs daily or the equivalent amount of yolk-free egg substitute over a 12
week period. 20 participants were assigned to the whole egg group and 17 to the
yolk-free egg substitute. Plasma lipids, apolipoproteins, oxidized LDL, cholesteryl
14

ester transfer protein (CETP) and lecithin-cholesterol acyltransferase (LCAT)
activities were assessed at baseline and week 12. Plasma triglycerides, apoC-III,
apoE, oxLDL, VLDL particle diameter, large VDL, total IDL, small LDL, and medium
LDL particles were reduced in all participants. HDL-C, large LDL, and large HDL
particles also increased in all participants. However, there were greater increases in
HDL-C and large HDL and reductions in VLDL and medium VLDL particles for those
consuming whole egg compared to substitute. LDL-C is an important risk factor
pertaining to CAD, however, the combination of all of the other categories have a far
greater impact on risk for cardiovascular event.
Another study focusing on nutritional approaches to reduce risk of CVD
focused on dietary intake of low saturated fat but a higher intake of red meat
presented results suggesting the intake of non-conventional foods for reducing
lipids and cholesterol could actually have a great impact on reducing risk of CAD.
Research based on beef in an optimal lean diet (BOLD diet) and the effects on lipids,
lipoproteins, and apolipoproteins contained data that reflected that participants
with the highest intake of red meat per day (~5.4 oz/day) had the most positive
impact on triglycerides and LDL-C levels. Participants all presented with
hypercholesterolemia (LDL-C >2.8 mmol/L) and were housed in a metabolic
kitchen. There is no mention of a structured physical activity program that may have
been followed. However, researchers were able to closely monitor daily behaviors
and provide detailed, nutrient dense meals including lean cuts of red meat that still
contains cholesterol. These lifestyle behaviors could have a positive impact on
serum 25(OH)D and IGF-1.¹⁸
15

This is supported by research conducted exploring the inverse relationship
between HDL-C or apolipoprotein A-I and cardiovascular events in women. Results
showed a consistent inverse association with HDL-C and coronary events among
participants with a range of LDL-C levels. An interesting portion of data within this
study also reflected that those participants with the highest HDL-C levels also had
the highest percentage of participants who exercised at least once or more per
week. This infers that those who were most active also had the highest level of HDLC. This group also resulted with the lowest percentage of individuals developing
diabetes, lowest percentage of smokers, lowest percentage of individuals developing
hypertension, the lowest level of apolipoprotein B100, the lowest triglyceride level,
and very nearly the lowest level of LDL-C.¹⁹
Impact of Physical Activity on Cardiovascular Disease
The concept of physical activity is a major catalyst when it comes to reducing
risk for CVD as well as reducing risk for obesity. Countless studies have reflected the
beneficial impact of physical activity on the human body. One such study conducted
suggested that time spent in vigorous activity is a significant indicator of total
cholesterol and LDL-C with waist girth being a sole predictor of triglycerides and
HDL-C. The study sought to explore the correlation of habitual exercisers, lean
sedentary men, and abdominally obese sedentary men to risk of CVD. A crosssectional study recruited 113 non-smoking men age 30-45 years. CVD risk factors
were assessed in these individuals and compared to exercisers, sedentary men, and
in subgroups of lean men, lean sedentary men, and obese sedentary men. Blood
pressure, physical activity (assessed with 7 day recall), physical fitness (assessed by
16

VO2 max), fasted lipoproteins, apolipoprotein B, triglycerides, glucose, and
fibrinogen were assessed. Results showed exercisers were leaner and fitter than
sedentary men and that leanness was associated with favorable HDL-C levels and
triglycerides with or without exercise. However, exercise contributed to also having
lower levels of total cholesterol, LDL-C, and apolipoprotein B. The subject group for
this study was for individuals aged 30-45 years which reflects an age group that
may still be active because they are still very ambulatory.²⁰
Further research on physical activity indicates that muscle damage caused by
exercise can up-regulate isoforms of IGF-1, primarily IGF-1Ea, IGF-1Eb, and IGF-1Ec.
These isoforms are known as mechano growth factors (MGF) and are produced
locally within the muscle. 10 healthy men were recruited, age 23-27 years, that were
physically active and had not participated in any type of resistance training or
regular exercise regime for at least 6 months prior to the study. Participants were
instructed to not consume any medication, nutritional supplements, and maintain
their habitual diet plans refraining from consuming alcohol through the duration of
the study. Maximal eccentric exercise protocol of the knee extensor muscles in each
leg was assessed in each participant. Biopsies and blood draws were taken in
intervals prior, during, and post exercise. Serum levels of IGF-1 did not reflect any
appreciable change, although MGF levels increased significantly. Increase in local
growth factors could result in a major complimentary reaction within the body and
increase insulin sensitivity.²¹
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Physical Activity in the Elderly
The elderly may not be able to participate in vigorous activity for various
reasons including disease or injury. Another study conducted included individuals
from a more elderly population. 2,772 individuals were randomly enrolled and
stratified by age and gender. Age ranged between 18-88 with the average age of
men 45 +/- 12 yrs and average age of women 45 +/- 13 yrs. Physically active women
showed a significantly lower level of serum cholesterol, LDL-C, and triglycerides.
Men did not show a significant difference between physically active men compared
to sedentary men, although the levels are more favorable in physically active men
reinforcing the concept that the more physically active an individual is, the lower
their risk of CVD.²²
Further research focused on physical activity primarily in the elderly
population. Long-term follow up data was collected on a total of 89 coronary artery
bypass graft (CABG) patients ranging from 55-88 years old. Subjects were divided
into two groups based on daily physical activity being greater or less than thirty
minutes. Surprisingly, only 26% of participants achieved the recommended thirty
minutes per day of moderate intensity activity. These individuals who were most
active again showed a more favorable profile of indicators of cardiovascular risk as
well as lower body mass. Subjects were objectively monitored with double-labeled
water, indirect calorimetry, pedometers, heart rate monitors, and accelerometry to
assess true daily activity level. Higher physical activity was associated with higher
apolipoprotein A-I levels and smaller apoB/apoAI ratios.²⁰
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Vitamin D and Skeletal Muscle
Emerging research suggests that there may be a relationship with vitamin D
and skeletal muscle mass, strength, and performance. No definitive mechanism has
been identified to how vitamin D exerts these benefits, however, there are many
rodent model as well as human model studies to support these suggestions. Vitamin
D has traditionally been regarded as a regulator of bone metabolism and serum
calcium and phosphate levels. Although, recent evidence suggests that the
biologically active form of vitamin D, 1, 25-dihydroxyvitamin D (1,25(OH)2D) has a
role in nuclear transcription as well as several components of cellular metabolism
via the vitamin D receptor (VDR). Mechanism of action and characterization has not
been well established for nonnuclear VDR, however, the binding of 1,25(OH)2D to
nonnuclear VDR is proposed to result in rapid cellular effects via formation of a
second messenger of intracellular proteins. Localized VDR have been identified in
human skeletal muscle through the use of biopsies.²³¯³⁴
Human aging may decrease expression of VDR and a positive association has
been found between 25(OH)D and VDR concentration in skeletal muscle. Recent
findings reflected an increase in VDR mRNA in human myoblasts treated with
1,25(OH)2D. Another study on 14 older, vitamin D deficient women discovered that
intramyonuclear VDR concentration increased 30% with vitamin D3
supplementation compared with placebo over a 4 month period.²³
1, 25(OH)2D is theorized to alter the activity of calcium pumps via a calcium
binding protein located in the sarcoplasmic reticulum and sarcolemma which will
impact muscle contraction by modulating cell calcium flux. Administration of 1,
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25(OH)2D regulates the expression of genes involved in these cellular processes of
calcium handling. Also, 1,25(OH)2D may increase calmodulin synthesis resulting in
influence on muscle contraction.²³ʼ²⁶¯³⁴
Research focusing on individuals with insulin resistance revealed that
decreased levels of serum 25(OH)D, 1,25(OH)2D, and elevated levels of serum
parathyroid hormone can lead to an increase in intracellular calcium in adipocytes,
which can stimulate lipogenesis further predisposing individuals to weight gain and
increase their risk of developing type 2 diabetes. Furthermore, administering
vitamin D to individuals with type 2 diabetes has been shown to decrease insulin
resistance. However, similar administration of vitamin D in individuals with
prediabetes has not been well established. 157 participants with prediabetes were
evaluated in the study and results showed that serum 25(OH)D had a relatively
strong inverse correlation with measures of insulin resistance and positive
correlation with insulin sensitivity.³¹¯³⁴
Vitamin D has also been shown to play a role in muscle growth by its effect
on anabolic signaling pathways. In a rat model study, rats consuming an alkali diet
receiving vitamin D3 supplementation enhanced phosphorylated Akt protein kinase
B (Akt) concentration which is an established component of the skeletal muscle
anabolic cascade. Upregulation of Akt will stimulate myogenesis in cells potentially
through a VDR mechanism.²³
Regulation of non-muscle tissue inflammation has also been related to
vitamin D status through suppression of several serum proinflammatory cytokines.
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This suggests that maintaining optimal levels of vitamin D may reduce risk of
atherosclerosis.²³
The notion of inflammation increasing risk for CVD is further supported by
research focusing on the sub-acute inflammation that accompanies obesity. Obesity
has been shown to increase inflammation in immune as well as parenchymal cells
within adipose tissue, liver, and vasculature. Within these tissues there is an
abnormal production of cytokines and chemokines that may further attract and
activate immune cells. Obese subjects also illicit increases in both amount and
activation of peripheral mononuclear cells and exhibit an increase in serum levels of
cytokines. Large scale studies contain evidence that markers of inflammation in
aggregate predict incident type 2 diabetes. A particularly interesting inclusion in the
study investigated reduction on inflammatory markers in patients who had
undergone Roux-en-Y bypass procedures and while the procedure resulted in a
marked reduction in adipose tissue macrophages and crown like structures, the
degree of improvement in insulin sensitivity 3 months post-surgery did not
correlate to adipose tissue macrophages.³⁴
Abdominal obesity has been shown to be a strong independent indicator of
25(OH)D status in humans with obese individuals presenting with insufficient or
deficient status. Although appropriate 25(OH)D status is still under debate in the
medical community, the Institute of Medicine currently defines vitamin D deficiency
as <50 nmol/L-1 or <20 ng/dL-1. 35 Two perspectives on why this occurs have come
to the forefront of research, however, evidence is limited for both. The first
perspective is that in vitro studies have reflected that the VDR and 1-α-hydroxylase
21

enzyme are present in adipose tissue. Researchers observed that 3T3-L1 preadipocytes express the VDR and subsequently that by 10 days after differentiation,
these adipocytes express receptors for vitamin D and parathyroid hormone (PTH).
Rat models recently found the presence of the 1-α-hydroxylase enzyme in these
3T3-L1 pre-adipocytes as well which is why adipose tissue is regarded as
metabolically active and may be regulated and regulate vitamin D. 36-42
The second perspective focuses on obese individuals having altered vitamin
D and PTH physiology. Several studies on obese patients reflect low levels of
circulating 25(OH)D and elevated levels of PTH. Much of the most recent
information on this phenomenon, is derived from research on bariatric surgery
patients. These patients report preoperatively with low circulating 25(OH)D (<80
nmol/L on average). Other studies on these patients also indicated that BMI and
body fat were inversely related to 25(OH)D. Despite the growing amount of
evidence to support the low levels of circulating 25(OH)D in obese individuals, the
relationship between obesity and the active form of vitamin D remains unclear due
to the natural endocrine response to elevate PTH when low circulating 25(OH)D is
present. This is where controversy lies. Some researchers have observed that the
best indicator of vitamin D status in overweight and obese individuals is the
substrate 25(OH)D while others have observed that the best indicator is the active
form 1, 25(OH)2D itself. 36-42 This raises the question, does obesity cause poor
vitamin D status or does poor vitamin D status cause obesity? Our research hopes to
contribute valuable information to further answer these questions.
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CHAPTER 3
METHODOLOGY
Subjects and Design
Subjects: As part of a cross-sectional correlation study, participants were males (7)
and females(19) (n=26), ages 25-65, who are students at UNLV and/or individuals
who attend local health and wellness facilities as well as attendees of classes held by
the UNLV Nutrition Center. Individuals were excluded if there were pregnant as this
may cause unusual hormone status.
Research Procedures: Participants reported to UNLV to review and sign informed
consent, complete a food frequency and physical activity questionnaire, and submit
a finger stick blood draw under sterile conditions as well as resting blood pressure
and waist circumference. Blood Pressure was obtained using a sphygmomanometer
and stethoscope taken on the right arm of each participant while in a seated
position. Waist circumference was obtained at the umbilicus using a flexible tape
measure.43 Questionnaires were administered prior to collecting blood pressure to
allow blood pressure to reach a resting rate. This study was reviewed and approved
by the UNLV Institutional Review for Biomedical Research.
Framingham Food Frequency Questionnaires (FFQ) were used to establish if
there were any unusual eating patterns as well as any supplementation taken by
participants. Framingham scores are considered the most reliable when predicting
risk of developing cardiovascular disease.44 The International Physical Activity
Questionnaires (IPAQ) was used to assess if there were unusual levels of physical
activity or unusual time spent indoors/outdoors. Both questionnaires have been
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validated to produce repeatable results.44-45 If participants were to report unusual
eating or physical activity behavior it could lead to obscure results.
Participants were then escorted to BHS 119 laboratory where sterile
instruments were used to obtain finger stick blood samples. The ring finger of the
participant’s non-dominant hand was prepped using 70% isopropyl alcohol swabs.
Terumo 1.5 mm width by 1.5 mm diameter were then used to penetrate the skin of
the finger and initiate blood draw. 600 µL were collected in Multivette 600 capillary
tubes. Once the target amount of blood was acquired, participants were given sterile
gauze dressing to be applied to wound for no less than two minutes as well as a
band aid to wear following the gauze protocol.
Blood was then spun using a centrifuge for no less than five minutes to
separate plasma. Plasma was then collected using a micro pipette with a sterile tip
for each sample and stored in Eppendorf tubes in -70 degree freezer for later
assessment. Remaining fluid was discarded following appropriate protocol in
biohazard waste containers.
Plasma samples collected were used to obtain serum 25(OH)D and IGF-1
levels using Immunodiagnostic System ELISA kits. 25-Hydroxyvitamin D
enzymeimmunoassay (EIA), product code AC-57F1, and IGF-1
immunoenzymometric assay (IEMA), product code AC-27F1 were used to determine
serum levels of each respective substrate.
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25(OH)D EIA Procedures: 25 µL of each calibrator and sample where combined with
1mL of 25-D Biotin Solution and mixed with a vortex machine thoroughly for 10
seconds. 200 µL of each diluted calibrator and sample where then placed in
appropriate wells in duplicate on the Antibody Coated Plate. Plate was then covered
with adhesive plate sealer (provided with kit) and left to incubate for 2 hours at
room temperature. Following incubation period, all wells were then washed 3 times
with 300 µL of Wash Solution. Following third wash, wells were then decanted by
inverting sharply. 250 µL of wash was added to all wells and decanting process was
repeated twice. 200 µL of Enzyme Conjugate was added to all wells using
multichannel pipette. Wash and decant process was then repeated. 200 µL of TMB
Substrate was added to all wells. Plate was covered again with adhesive plate sealer
and set aside to incubate for 30 minutes. Following incubation, 100 µL of Stop
Solution was added to all wells. Absorbance was then measured using microplate
reader and results were calculated.
Figure 1: 25-Hydroxyvitamin D ELISA Results

25(OH)D ELISA

M
e
a
n

A
b
s
o
r
b
a
n
c
e

3
2.5
2
1.5
y = -1.1742x + 3.7638
1 R² = 0.9709
0.5
0
0
1
2
Log Concentration
25(OH)D

25

Series1
Linear (Series1)
3

IGF-1 IEMA Procedures: 25 µL of each calibrator and sample were combined with
100 µL of Releasing Reagent, vortexed for thoroughly, and set aside to incubate at
room temperature for 10 minutes. 1.0 mL of Sample Diluent was added to each and
vortexed thoroughly. 50 µL of each diluted calibrator and sample was then added in
duplicate to appropriate wells of the Antibody Coated Plate. 200 µL of Enzyme
Conjugate was added to all wells using a multichannel pipette. Plate was then set
aside to incubate for 2 hours at room temperature. Following incubation, wells were
washed 3 times with 300 µL of Wash Solution. Following third wash, wells were
then decanted by inverting sharply. 250 µL of wash was added to all wells and
decanting process was repeated twice. 200 µL of TMB Substrate was added to all
wells using a multichannel pipette and set aside to incubate for 30 minutes.
Following incubation, 100 µL of Stop Solution was added to all wells. Absorbance
was then measured using microplate reader and results were calculated.
Figure 2: IGF-1 ELISA Results
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4

Metabolic Panel: Participants then reported to a local Quest Diagnostics at their
convenience to obtain a fasting comprehensive metabolic panel. Data were collected
and analyzed using a paired t-test.
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CHAPTER 4
FINDINGS
Table 1: Participant Data
Participant
1
2
3
4
6
7
10
11
12
A
C
E
H
J
K
L
MEAN
STDEV

Participant
5
8
9
13
B
D
F
G
I
M
MEAN
STDEV

Gender
F
M
M
F
F
F
F
F
F
F
F
M
M
F
F
M

M
F
F
M
F
F
F
F
F
F

25(OH)D
IGF-1
Waist Cir nmol/L
µg/L
29
163.9
109.5
34.5
54.4
63.2
34
104.6
47.1
25.75
170.1
90.2
26
133.9
53.7
31.25
102.9
57.2
33.5
297.5
41.5
30.5
216.5
78.1
28.5
239.5
69.1
29.5
97.8
53.7
29
115.7
50.9
31
150.8
66.8
36
147.1
48.3
26.5
144.1
75.6
28.5
140.2
79.4
30.5
301.3
59.3
30.25
161.26875
65.225
3.050956 69.93581551 17.94096
25(OH)D
IGF-1
Waist Cir nmol/L
µg/L
48
268.9
40.6
39
67.3
78
38
158.9
68.6
48
154.9
63.8
40.5
65.6
36.6
35.5
83.2
46.6
45
157.1
41.2
36.5
144.8
54.7
37
45
75.5
39
258
46.2
40.65
140.37
55.18
4.672912
77.8205921 15.25988

Table 1 reflects data collected from each participant regarding gender, waist
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circumference, 25(OH)D, and IGF-1 levels. Participants are separated according to
waist circumference group with normal waist circumference in the upper portion
and large waist circumference in the lower portion.
Table 2: t-Test Assuming Equal Variances: Waist Circumference
t-Test: Two-Sample Assuming Equal Variances

Waist Circumference

Mean
Variance
Observations
Pooled Variance
Hypothesized Mean Difference
df
t Stat
P(T<=t) one-tail
t Critical one-tail
P(T<=t) two-tail
t Critical two-tail

Variable 1 Variable 2
30.25
40.65
9.308333 21.83611
16
10
14.00625
0
24
-6.89359
1.98E-07
1.710882
3.96E-07
2.063899

Table 2 reflects data collected regarding the waist circumference of participants of
both genders resulted in a significant difference between the normal waist
circumference group and the large waist circumference group (P = 0.000002).
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Relationship between IGF-1, and Waist Circumference
Figure 3: Scatter Plot Correlation of IGF-1 to Waist Circumference

Figure 3 reflects data collected regarding the correlation between waist
circumference and IGF-1. Results found a significant correlation between waist
circumference and IGF-1 (P=.006)
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Table 3: Correlation of IGF-1 to Waist Circumference
Correlations
Waist_Circumfer
ence
Waist_Circumference

Pearson Correlation

IGF1
1

Sig. (2-tailed)

.006

N
IGF1

-.525**

Pearson Correlation
Sig. (2-tailed)

26

26

-.525**

1

.006

N

26

26

Table 3 reflects data collected regarding the correlation between waist
circumference and IGF-1. Results found a significant correlation between waist
circumference and IGF-1 (P=.006)
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Relationship between 25-Hydroxyvitamin D and Waist Circumference
Figure 4: Scatter Plot of 25(OH)D to Waist Circumference

Figure 4 reflects data collected regarding the correlation between waist
circumference and 25(OH)D. No significant difference was found (P = 0.649).
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Table 4: Correlation of 25(OH)D to Waist Circumference
Correlations
Waist_Circumfer
ence
Waist_Circumference

VITD

Pearson Correlation

1

Sig. (2-tailed)

.649

N
VITD

-.094

Pearson Correlation

26

26

-.094

1

Sig. (2-tailed)

.649

N

26

26

Table 4 reflects data collected regarding the correlation between waist
circumference and 25(OH)D. No significant difference was found (P = 0.649).
Table 5: t-Test Assuming Equal Variances IGF-1
t-Test: Two-Sample Assuming Equal Variances

IGF-1

Mean
Variance
Observations
Pooled Variance
Hypothesized Mean Difference
df
t Stat
P(T<=t) one-tail
t Critical one-tail
P(T<=t) two-tail
t Critical two-tail

Variable Variable
1
2
65.225
55.18
321.878 232.864
16
10
288.4978
0
24
1.467074
0.077669
1.710882
0.155339
2.063899

Table 5 reflects data in regards to large waist and normal waist circumference
groups and their level of IGF-1. No significant difference was found between the
groups (P=0.08).
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Table 6: t-Test Assuming Equal Variances 25(OH)D
t-Test: Two-Sample Assuming Equal Variances 25(OH)D

Mean
Variance
Observations
Pooled Variance
Hypothesized Mean Difference
df
t Stat
P(T<=t) one-tail
t Critical one-tail
P(T<=t) two-tail
t Critical two-tail

Variable
1
Variable 2
161.2688
140.37
4891.018 6056.044556
16
10
5327.903
0
24
0.710257
0.242195
1.710882
0.48439
2.063899

Table 6 reflects data in regards to large waist and normal waist circumference
groups and their level of 25(OH)D. No significant difference was found between the
groups (P=0.24).
Groups were also separated according to gender and the same statistical
analysis were evaluated. Within our data set, gender did not seem to influence
results, however, our sample group contained primarily female participants. Data
collected reflects a definitive separation of participant groups according to waist
circumference to be used to assess other relationships within the data.
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CHAPTER 5
DICUSSION AND IMPLICATIONS
Discussion
The purpose of this study was to assess if there was a relationship between
25(OH)D, IGF-1, and waist circumference. A significant relationship was found
between IGF-1 and waist circumference, however, 25(OH)D was not found to have a
significant relationship to waist circumference. No significant difference was found
in both IGF-1 and 25(OH)D between large waist and normal waist circumference
groups. It is worth mentioning that only 5 of the 26 participants presented with
sufficient IGF-1 (according to normal reference range17). Also, only 1 participant
presented with 25(OH)D levels borderline insufficient.
Table 7: Normal Reference Range IGF-1
21-25 years 83-344

21-25 years 84-323

26-30 years 75-275

26-30 years 77-271

31-35 years 71-241

31-35 years 73-244

36-40 years 69-226

36-40 years 68-225

41-45 years 64-210

41-45 years 62-205

46-50 years 59-201

46-50 years 56-194

51-55 years 56-201

51-55 years 53-191

56-60 years 51-194

56-60 years 45-173

61-65 years 47-191

61-65 years 41-168

Males

Females

Table 7 indicates normal reference ranges of free IGF-1 according to information
derived from Mayo Clinic Laboratories.17
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This research project was unique from other similar research projects in the
ability of investigators to interact personally and obtain detailed information
regarding nutritional intake and physical activity. According to data collected in
food frequency and physical activity questionnaires, all participants ate a relatively
well-balanced diet that included decent sources of vitamin D. All participants also
maintained a relatively active lifestyle. Active lifestyles could enhance the
participant’s insulin sensitivity as well as up-regulate IGF-1 production allowing for
their IGF-1 to operate more efficiently. However, our results indicated that the
majority of participants still exhibited low levels of IGF-1.
Another aspect to consider is that data was collected in the later part of
spring and early summer in a desert climate. Participants could easily obtain
additional vitamin D from being outside. Within our data set, gender did not seem to
influence results, however, our sample group contained primarily female
participants. Future research including a larger representation of male population
would be beneficial to identify possible relationships between 25(OH)D, and waist
circumference.
Conclusion
Risks associated with large waist circumference, low IGF-1, and low 25(OH)D
can lead to metabolic syndrome and if left untreated can be fatal. These risks also
include a variety of complications such as; higher risk of cardiovascular event, sleep
apnea, aortic stiffness, hypertension, joint pain, respiratory distress, and all of the
complications involved will compound each other furthering progression of the
syndrome. All of the conditions of metabolic syndrome can be controlled through
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diet, exercise, and lifestyle changes, however, few patients are able to make or
adhere to the necessary changes to reduce the risk involved.
Both ELISA kits displayed acceptable accuracy. Despite all participants
displaying sufficient amounts of serum 25(OH)D, only 5 participants displayed
sufficient serum IGF-1. Insufficient serum IGF-1 may suggest possible human
growth hormone (HGH) deficiency, however, more information regarding
participants’ IGF-1 binding proteins would be required to fully assess this condition.
Theoretically, evidence reviewed in this project suggests that insufficient serum
IGF-1 levels can be treated pharmaceutically as well as through lifestyle
modification.
Future Research
Future research including accurate information regarding all binding
proteins of IGF-1 as well as a more detailed account of daily behavior by a larger
sample of participants would very useful in assessing relationships between
25(OH)D, IGF-1, and waist circumference. Large waist circumference could be
related to many risk factors for disease, however, maintaining a relatively active
lifestyle may slightly reduce the risk for individuals who have large waist
circumferences. Obtaining waist circumference as well as activity level is relatively
convenient in medical treatment settings and could provide clinicians with more
valuable information regarding patient’s level of risk for disease. This information
could provide researchers and clinicians with practical information that could be
used to formulate patient care plans that could greatly reduce their risk for
cardiovascular event.
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APPENDIX I: INFORMED CONCENT
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APPENDIX II: FOOD FREQUENCY QUESTIONNAIRE
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APPENDIX III: PHYSICAL ACTIVITY QUESTIONNAIRE
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APPENDIX IV: DESCRIPTIVE STATISTICS FOR ALL SUBJECTS
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APPENDIX V: IGF-1 ELISA RESULTS

OD 1
0.615
0.415
0.295
0.497
0.234
0.335
0.367
0.476
0.423
0.237
0.482
0.445
0.444
0.329
0.19
0.317
0.289
0.458
0.236
0.36
0.279
0.5
0.489
0.493
0.384
0.274

OD 2
0.61
0.39
0.286
0.58
0.233
0.345
0.362
0.49
0.444
0.246
0.485
0.428
0.368
0.351
0.197
0.324
0.283
0.389
0.242
0.334
0.32
0.441
0.455
0.486
0.372
0.291

MEAN
0.6125
0.4025
0.2905
0.5385
0.2335
0.34
0.3645
0.483
0.4335
0.2415
0.4835
0.4365
0.406
0.34
0.1935
0.3205
0.286
0.4235
0.239
0.347
0.2995
0.4705
0.472
0.4895
0.378
0.2825
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LOGMEAN
2.039568
1.800796
1.673451
1.955429
1.608641
1.729733
1.75759
1.892325
1.836043
1.617737
1.892894
1.839454
1.804775
1.729733
1.563161
1.707561
1.668334
1.824673
1.614895
1.737692
1.683684
1.878113
1.879818
1.899716
1.772939
1.664355

CONC
109.5
63.2
47.1
90.2
40.6
53.7
57.2
78
68.6
41.5
78.1
69.1
63.8
53.7
36.6
50.9
46.6
66.8
41.2
54.7
48.3
75.5
75.6
79.4
59.3
46.2

APPENDIX VI: IGF-1 ELISA VALIDATION
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APPENDIX VII: 25(OH)D ELISA RESULTS

OD 1
1.431
1.763
1.784
1.422
0.939
1.738
1.874
1.726
1.201
0.903
1.047
1.171
1.398
2.005
1.631
1.726
1.201
0.903
1.047
1.171
1.398
2.005
1.631
1.088
0.923
0.914

OD 2
0.896
1.688
1.001
0.867
0.883
0.795
0.928
1.508
1.157
0.816
0.996
0.769
0.986
0.848
1.63
0.956
1.817
1.509
1.323
1.282
1.039
1.64
0.827
1.398
0.783
0.95

MEAN LOGMEAN
1.1635
2.214529
1.7255
1.735905
1.3925
2.019503
1.1445
2.23071
0.911
2.429569
1.2665
2.12681
1.401
2.012264
1.617
1.828309
1.179
2.201329
0.8595
2.473429
1.0215
2.335462
0.97
2.379322
1.192
2.190257
1.4265
1.990547
1.6305
1.816811
1.341
2.063362
1.509
1.920286
1.206
2.178334
1.185
2.196219
1.2265
2.160875
1.2185
2.167689
1.8225
1.653296
1.229
2.158746
1.243
2.146823
0.853
2.478964
0.932
2.411685
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CONC
163.9
54.4
104.6
170.1
268.9
133.9
102.9
67.3
158.9
297.5
216.5
239.5
154.9
97.8
65.6
115.7
83.2
150.8
157.1
144.8
147.1
45
144.1
140.2
301.3
258

APPENDIX VIII: 25(OH)D ELISA VALIDATION

25(OH)D ELISA
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APPENDIX IX: t-TEST ASSUMING EQUAL VARIANCES: WAIST
CIRCUMFERENCE

t-Test: Two-Sample Assuming Equal Variances

Waist Circumference

Mean
Variance
Observations
Pooled Variance
Hypothesized Mean Difference
df
t Stat
P(T<=t) one-tail
t Critical one-tail
P(T<=t) two-tail
t Critical two-tail

Variable 1 Variable 2
30.25
40.65
9.308333 21.83611
16
10
14.00625
0
24
-6.89359
1.98E-07
1.710882
3.96E-07
2.063899
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APPENDIX X: t-TEST ASSUMING EQUAL VARIANCES: IGF-1

t-Test: Two-Sample Assuming Equal Variances

IGF-1

Mean
Variance
Observations
Pooled Variance
Hypothesized Mean Difference
df
t Stat
P(T<=t) one-tail
t Critical one-tail
P(T<=t) two-tail
t Critical two-tail

Variable 1 Variable 2
65.225
55.18
321.878 232.864
16
10
288.4978
0
24
1.467074
0.077669
1.710882
0.155339
2.063899
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APPENDIX XI: t-TEST ASSUMING EQUAL VARIANCES: 25(OH)D

t-Test: Two-Sample Assuming Equal Variances Vitamin D
Variable 1
Variable 2
Mean
161.2688
140.37
Variance 4891.018
6056.044556
Observations
16
10
Pooled Variance
5327.903
Hypothesized Mean0Difference
df
24
t Stat
0.710257
P(T<=t) one-tail
0.242195
t Critical one-tail
1.710882
P(T<=t) two-tail
0.48439
t Critical two-tail
2.063899
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